Onderneming Northwest Biotherapeutics, Inc Nasdaq
Aandelen
US66737P6007
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17-05-07 |
Alton L. Boynton
FOU | Founder | 79 | 18-03-96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01-01-00 |
David Innes
IRC | Investor Relations Contact | - | 26-02-19 |
General Counsel | 78 | 01-06-11 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 18-03-96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 17-05-07 |
Navid Malik
BRD | Director/Board Member | 55 | 01-04-12 |
Director/Board Member | 74 | 27-01-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 200 000 | 0 | 0 | 90,82 % |
Aandeel B | 1 | 1 208 177 416 | 1 097 287 981 ( 90,82 %) | 0 |
Bedrijfsgegevens
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,86% | 114 mld. | |
+11,51% | 104 mld. | |
-12,55% | 22,41 mld. | |
-1,05% | 22,28 mld. | |
-5,29% | 19,07 mld. | |
-38,29% | 18 mld. | |
-3,10% | 17,89 mld. | |
+7,82% | 14,28 mld. | |
+35,85% | 12,55 mld. |